Next Article in Journal
Use of a Novel Enhanced DNA Vaccine Vector for Preclinical Virus Vaccine Investigation
Previous Article in Journal
Childhood Immunization in Ethiopia: Accuracy of Maternal Recall Compared to Vaccination Cards
Article Menu

Export Article

Open AccessBrief Report

Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform

1
Department of Microbiology, Infectiology and Immunology, faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada
2
Department of Neurosciences, faculty of Medicine, Laval University, Quebec City, QC G1V 4G2, Canada
*
Author to whom correspondence should be addressed.
Vaccines 2019, 7(2), 49; https://doi.org/10.3390/vaccines7020049
Received: 13 May 2019 / Revised: 6 June 2019 / Accepted: 8 June 2019 / Published: 12 June 2019
(This article belongs to the Section Vaccines against Infectious Diseases)
  |  
PDF [978 KB, uploaded 12 June 2019]
  |     |  

Abstract

Background: Flexuous rod-shape nanoparticles—made of the coat protein of papaya mosaic virus (PapMV)—provide a promising vaccine platform for the presentation of viral antigens to immune cells. The PapMV nanoparticles can be combined with viral antigens or covalently linked to them. The coupling to PapMV was shown to improve the immune response triggered against peptide antigens (<39 amino acids) but it remains to be tested if large proteins can be coupled to this platform and if the coupling will lead to an immune response improvement. Methods: Two full-length recombinant viral proteins, the influenza nucleoprotein (NP) and the simian immunodeficiency virus group-specific protein antigen (GAG) were coupled to PapMV nanoparticles using sortase A. Mice were immunized with the nanoparticles coupled to the antigens and the immune response directed to the antigens were analyzed by ELISA and ELISPOT. Results: We showed the feasibility of coupling two different full-length proteins (GAG and NP) to the nanoparticle. We also showed that the coupling to PapMV nanoparticles improved significantly the humoral and the cytotoxic T lymphocyte (CTL) immune response to the antigens. Conclusion: This proof of concept demonstrates the versatility and the efficacy of the PapMV vaccine platform in the design of vaccines against viral diseases. View Full-Text
Keywords: vaccine platform; nanoparticle; papaya mosaic virus vaccine platform; nanoparticle; papaya mosaic virus
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Laliberté-Gagné, M.-È.; Bolduc, M.; Thérien, A.; Garneau, C.; Casault, P.; Savard, P.; Estaquier, J.; Leclerc, D. Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform. Vaccines 2019, 7, 49.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top